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D’Alessio, David A., and Torsten P. Vahl. Glucagon-like peptide 1: evolution
of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 286:
E882–E890, 2004; 10.1152/ajpendo.00014.2004.—Glucagon-like peptide 1
(GLP-1) is a product of proglucagon that is secreted by specialized intestinal
endocrine cells after meals. GLP-1 is insulinotropic and plays a role in the incretin
effect, the augmented insulin response observed when glucose is absorbed through
the gut. GLP-1 also appears to regulate a number of processes that reduce
ﬂuctuations in blood glucose, such as gastric emptying, glucagon secretion, food
intake, and possibly glucose production and glucose uptake. These effects, in
addition to the stimulation of insulin secretion, suggest a broad role for GLP-1 as
a mediator of postprandial glucose homeostasis. Consistent with this role, the most
prominent effect of experimental blockade of GLP-1 signaling is an increase in
blood glucose. Recent data also suggest that GLP-1 is involved in the regulation of
-cell mass. Whereas other insulinotropic gastrointestinal hormones are relatively
ineffective in stimulating insulin secretion in persons with type 2 diabetes, GLP-1
retains this action and is very effective in lowering blood glucose levels in these
patients. There are currently a number of products in development that utilize the
GLP-1-signaling system as a mechanism for the treatment of diabetes. These
compounds, GLP-1 receptor agonists and agents that retard the metabolism of
native GLP-1, have shown promising results in clinical trials. The application of
GLP-1 to clinical use fulﬁlls a long-standing interest in adapting endogenous
insulinotropic hormones to the treatment of diabetes.
glucose tolerance; insulin secretion
IT HAS LONG BEEN KNOWN that the assimilation of glucose is
more efﬁcient when it is given orally than when it is given
intravenously. The primary explanation for this is that
factors released from the gastrointestinal (GI) tract regulate
insulin secretion and glucose homeostasis. Thus circulating
insulin levels are signiﬁcantly higher after glucose is in-
gested than when it is administered intravenously, and the
enhanced insulinotropic potency of glucose absorbed
through the GI tract is attributed to the actions of hormones
released from the gut. These hormones are termed incretins,
and the augmentation of insulin secretion with oral com-
pared with intravenous glucose is termed the incretin effect.
There are two known hormones that act as incretins, glu-
cose-dependent insulinotropic polypeptide (GIP) and gluca-
gon-like peptide 1 (GLP-1). These peptides are produced by
specialized cells in the intestinal mucosa and secreted in
response to carbohydrate- and lipid-containing meals. There
are speciﬁc GIP and GLP-1 receptors that are expressed on
islet cells, as well as in other tissues, and deletion of these
receptors in mouse models leads to glucose intolerance (13).
These data and corroborating studies using GIP and GLP-1
receptor antagonists have demonstrated that so-called “en-
teroinsular” signaling is a physiological process that is
necessary for normal glucose homeostasis (15, 21, 42, 99).
The physiological actions of the incretins raise the possibil-
ity that these naturally occurring peptides could be harnessed
for the treatment of diabetes. However, although there is
considerable homology between GIP and GLP-1, and the
peptides seem to act through similar mechanisms in -cells,
there is a great divergence in the clinical potential of the
incretins. GIP is relatively ineffective in eliciting insulin se-
cretion in individuals with type 2 diabetes (26, 56) and so has
not been intensively pursued as a therapeutic agent. On the
other hand, GLP-1 is insulinotropic in diabetic as well as
nondiabetic humans and also seems to promote glucose ho-
meostasis beyond the enhancement of insulin secretion. In a
number of experimental settings, GLP-1 has been very effec-
tive in correcting the hyperglycemia of diabetic subjects, and
several pharmacological agents that act by enhancing GLP-1
signaling are in advanced development.
This minireview will summarize the physiological actions of
GLP-1 that are involved in controlling blood glucose levels in
healthy and diabetic humans, discuss the evidence that these
effects are due to an integration of GLP-1 actions on several
organ systems, and brieﬂy describe the development of GLP-
1-based pharmaceuticals. For more information on the under-
lying molecular and cellular physiology of the incretins and
their synthesis and secretion, several excellent reviews have
been published in the recent past (17, 19, 36, 40).
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Because GLP-1 has been identiﬁed as an incretin, it is often
characterized primarily as an insulin secretagogue. However,
whereas stimulation of -cell secretion is probably a prominent
physiological action of GLP-1, it is better classiﬁed as a
hormone that regulates glucose homeostasis rather than as just
an incretin. For example, when the action of GLP-1 is blocked
in humans or nonhuman primates during glucose ingestion, the
most notable response is an increase in blood glucose (15, 21).
In humans this response is accompanied by a small increase in
plasma insulin. In nonhuman primates there is equivalent
insulin secretion, compared with controls without GLP-1 re-
ceptor blockade (Fig. 1). Given the consensus role of GLP-1 as
a stimulus for postprandial insulin release, these ﬁndings ap-
pear at ﬁrst paradoxical. One interpretation of these data is that
the increase in circulating glucose levels that occurs when
GLP-1 signaling is abolished or blunted stimulates increased
insulin secretion directly or by increasing the gain of other
postprandial -cell stimuli. In fact, the effect of even small
increases in plasma glucose levels to potentiate GIP-stimulated
insulin secretion has recently been demonstrated (95). A sec-
ond interpretation of the more pronounced effect of GLP-1
blockade on blood glucose than on insulin concentrations is
that GLP-1 regulates other functions contributing to glucose
tolerance beyond insulin secretion. Indeed, there is consider-
able evidence that GLP-1 regulates gastric function, glucagon
secretion, and possibly other systems that govern circulating
glucose concentrations. The action of GLP-1 is thus a com-
posite of several processes acting on blood glucose during the
postprandial state, and the role of any one of these can be
difﬁcult to discern in vivo. Most probably, elements of both of
these explanations of the effects of GLP-1 blockade are true.
Nonetheless, when the physiology and pharmacology of
GLP-1 are considered, plasma glycemia is generally the pa-
rameter most reﬂective of GLP-1 effects.
PHYSIOLOGICAL ACTIONS OF GLP-1 THAT PROMOTE
GLUCOSE HOMEOSTASIS
Signaling Through the GLP-1 Receptor
A speciﬁc GLP-1 receptor has been cloned from pancreatic
islet cells (40) and is the only known mediator of GLP-1
signaling in mammals. The mRNA for this receptor has been
demonstrated in speciﬁc regions of the stomach, heart, kidney,
and lung as well as islet cells (6). The GLP-1 receptor is also
expressed in speciﬁc regions of the brain, where it mediates a
number of behaviors, such as satiety and the response to illness
(78, 88). There are also emerging data suggesting that the
GLP-1 receptor is expressed by visceral afferent nerves (55,
61), and several studies suggest that some of the actions of
GLP-1 secreted from the GI tract could be mediated via
autonomic neural pathways (4, 8, 37, 100).
The GLP-1 receptor is a member of the secretin-VIP family
of seven membrane-spanning, G protein-coupled receptors (36,
40). Ligand binding by this receptor is highly speciﬁc, and
there is little afﬁnity for glucagon or GIP. However, exendin-4,
a peptide found in the venom of the Gila monster (Heloderma
suspectum), and its derivative exendin-4-(9–39), are a natu-
rally occurring GLP-1 receptor agonist and antagonist, respec-
tively (54). In cultured -cells, GLP-1 mediates its effects
through G proteins linked to adenylyl cyclase, formation of
intracellular cAMP, and activation of protein kinase A (PKA)
(32). Foremost among these effects are synergism with glucose
to close ATP-sensitive channels, augmentation of glucose-
induced increases in intracellular calcium, and promotion of
secretory granule exocytosis. In addition, it has recently been
shown that a signiﬁcant component of GLP-1 signaling is
independent of PKA and acts through the cAMP-regulated
guanine nucleotide exchange factor II pathway (5, 39).
A hallmark of the insulinotropic effect of GLP-1 is the
dependence on ambient glucose levels, and GLP-1 has only
minimal activity on insulin secretion at fasting or basal glucose
concentrations (40). The mechanism conferring glucose depen-
dence is not fully understood, but it has been suggested to
result from independent effects of GLP-1 to facilitate ATP
generation from glucose (87), differential effects of PKA in
states of high or low intracellular ADP (46), and/or the effect
of GLP-1 to inhibit voltage-dependent potassium channels that
are quiescent at basal glucose levels but activated by hyper-
glycemia (49). Regardless, the attenuated insulinotropic effect
of GLP-1 at basal glycemia can be seen as a physiological
adaptation to protect against incretin-induced hypoglycemia.
Fig. 1. Plasma glucose (A) and insulin (B) in 4 macaques given the glucagon-
like peptide 1 (GLP-1) receptor antagonist exendin-(9–39) or saline during
intragastric glucose loading. Glycemic excursion is signiﬁcantly greater with
blockade of GLP-1 action, but integrated insulin responses are not different.
Taken from Ref. 15.
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from other insulin secretagogues such as sulfonylureas, which
induce insulin secretion independently of the glucose concen-
tration.
Effects of GLP-1 on -Cell Function
Administration of GLP-1 to animals and humans increases
insulin secretion when blood glucose is increased above basal
levels. Because this effect occurs at concentrations of GLP-1
immunoreactivity that are similar to those observed in the
circulation after meals, it has been assumed that this represents
a physiological action. Indeed, two studies of rats given the
GLP-1 receptor antagonist exendin-(9–39) demonstrated de-
creased insulin levels and glucose intolerance during the ab-
sorption of glucose from the gut (42, 99). Similarly, male mice
with a targeted deletion of the GLP-1 receptor gene also had
hyperglycemia and a mild impairment of insulin release after a
glucose gavage (77). These results in rats and mice diverge
from the effects of GLP-1 receptor blockade in other species,
since monkeys given exendin-(9–39) during intragastric glu-
cose tolerance tests had elevated postprandial glucose but with
overall insulin secretion that was comparable to that of controls
(15), and humans given this GLP-1 receptor blocker had
increased postprandial glycemia associated with increased
plasma insulin (21). The reason for the difference in ﬁndings
between rodents and primates has not been explained and
might suggest a greater importance of GLP-1 in the regulation
of insulin secretion in rats and mice. Regardless, when the data
from studies in mammals are considered as a whole, they
indicate that GLP-1 is necessary for normal glucose tolerance
and postprandial insulin release.
In addition to abnormalities in the insulin and glucose
responses to ingested glucose, GLP-1 receptor-deﬁcient mice
have fasting hyperglycemia and impaired insulin secretion in
response to parenteral glucose (77). Although this latter ﬁnding
is puzzling at ﬁrst glance, since GLP-1 levels in the circulation
are low except during meal absorption, recent studies in vitro
(79) and in humans (75) suggest that basal levels of GLP-1
may play a role in -cell function. The observation that GLP-1
receptor knockout mice have decreased pancreatic insulin and
insulin mRNA content (65) is also consistent with the notion
that basal, or the long-standing integrated, levels of GLP-1
have important effects on -cell function. Other studies have
shown that GLP-1 increases insulin biosynthesis and stimulates
the transcription of other -cell genes, including glucokinase
and the GLUT2 glucose transporter (98). GLP-1 also increases
the capacity of individual -cells to respond to stimulation by
glucose, and this effect to activate glucose-insensitive cells has
been termed induction of glucose competence (36). Further-
more, a recent study in rats with -cell damage after strepto-
zotocin treatment supported a role for -cell-derived GLP-1 in
the promotion of insulin secretion (59). These cumulative data
suggest that GLP-1 may have important effects on -cell
function beyond incretin action as an acute insulin secreta-
gogue.
Other Actions of GLP-1 that Promote Glucose Homeostasis
Importantly, GLP-1 has been shown to have effects on
tissues other than the pancreatic -cell, and these extraislet
actions are ones that promote glucose homeostasis. In general,
the extraislet functions of GLP-1 have been most clearly
demonstrated in studies using exogenous peptide, and func-
tions in normal physiology have not been conclusively estab-
lished. Nonetheless, a reasonable case can be made that GLP-1
has a broad role to minimize ﬂuctuations in blood glucose
levels by regulating some of these extra--cell processes.
GLP-1 lowers fasting and postprandial glucagon concentra-
tions in humans, animals, and cultured islets (40). Although the
GLP-1 receptor has been demonstrated on -cells, it is also
possible that the effect of GLP-1 on glucagon secretion is
mediated in a paracrine manner via insulin or somatostatin.
Because fasting glucagon levels increase when the GLP-1
receptor is blocked with exendin-(9–39), at a time when
GLP-1 levels are at basal it appears that there may be tonic
regulation of the -cell by GLP-1 (15, 75). These data indicate
that GLP-1 coordinates the secretion of islet hormones in a
manner that minimizes elevations in blood glucose.
Doses of GLP-1 estimated to mimic postprandial plasma
concentrations inhibit antral contractions, increase pyloric
tone, and substantially lower the rate of gastric emptying of
both liquid and solid meals (74). This effect is sufﬁcient to
minimize the rise in meal-induced glucose and insulin levels,
and supraphysiological doses of GLP-1 virtually abolish gas-
tric emptying over the course of several hours. However, two
recent studies demonstrated that GLP-1 also relaxes the prox-
imal stomach and increases gastric capacity (16, 76). These
effects of GLP-1 on gastric motility, as well as an action to
inhibit gastric acid secretion, are likely mediated through vagal
afferent nerves (37, 100). The complex actions of GLP-1 on
gastric function suggest that this is a physiological role for the
peptide, but this has not been proven. In humans given infu-
sions of GLP-1 to mimic physiological concentrations, gastric
emptying of solid meals was signiﬁcantly delayed (31). How-
ever, in nonhuman primates given exendin-(9–39) during oral
glucose tolerance tests, no difference in delivery of carbohy-
drate to the intestine was noted (15), suggesting that, with
small liquid meals, the effect of GLP-1 to slow gastric emp-
tying may be small. Although more work is needed to establish
the physiological role of GLP-1 on gastric function, it is clear
that exogenous GLP-1 has powerful effects on the stomach.
GLP-1 is produced by a discrete set of neurons in the
hindbrain, and administration of GLP-1 into the cerebroven-
tricular system of rats decreases food intake (88). This raises
the possibility that GLP-1 may have a regulatory role in satiety
or body weight regulation. Because short-term intravenous
administration of GLP-1 to humans suppresses consumption of
a subsequent lunch (30, 34), it appears that at least some of the
satiety effects of GLP-1 are mediated by peripherally, rather
than centrally, derived peptide. One possibility is that effects of
GLP-1 on food intake are mediated through the same visceral
neural circuits that regulate gastric emptying. Although there is
still some question as to whether GLP-1 regulates energy
balance and body weight, reduction of food intake can be
viewed as another mechanism by which GLP-1 minimizes
postprandial glucose excursions.
There have been several studies in humans demonstrating
that GLP-1 decreases blood glucose concentrations indepen-
dently of the islet hormones (Table 1 and Refs. 14, 24, 33, 51,
52, 80, and 90). However, a number of other studies designed
to determine whether there are extraislet actions of GLP-1 have
been negative (Table 1 and Refs. 73, 84, 91, 92). It is likely that
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variation in experimental methods used by different investiga-
tors and the relatively small effect of reported extraislet effects,
generally 15% of glucose disposition. There are several
studies indicating that GLP-1 does not acutely affect insulin
sensitivity in humans (1, 14, 63, 73, 87, 88), although there are
some reports of GLP-1 augmenting insulin action (24, 51). The
several reports suggesting that GLP-1 has independent effects
to promote glucose disposal are consistent with in vitro studies
showing that GLP-1 promotes glucose uptake in cultured cells
(25, 62) and in animals (60). It has recently been reported that
GLP-1 suppressed fasting glucose production while insulin and
glucagon levels were ﬁxed with a clamp technique (67).
Although this ﬁnding would appear to be at odds with solid
evidence that the GLP-1 receptor is not expressed in hepato-
cytes (6), it is plausible that GLP-1 effects on hepatic glucose
production could also be regulated by visceral nerves similar to
gastric function. Overall, although islet-independent actions of
GLP-1 to regulate plasma glucose continue to be both elusive
and controversial, this area of investigation remains intriguing
because of its novel physiological implications and potential
therapeutic application.
Incretins and Islet Growth
An exciting new aspect of GLP-1 biology is an apparent role
in pancreatic islet growth and development. Recent studies in
rodents have shown that GLP-1 and its analogs directly stim-
ulate -cell growth and replication to promote an increase in
islet mass (18, 81, 101). These initial reports have been
buttressed by a series of recent studies indicating that GLP-1
receptor agonists cause the differentiation of pancreatic duct
cells into insulin-producing cells (7, 35). In addition, there is
now evidence that GLP-1 inhibits -cell apoptosis, another
action that would promote expansion of -cell mass (28, 45,
97). In contrast to the primary role of cAMP in the acute
stimulation of insulin secretion, GLP-1-mediated -cell growth
is likely activated with the phosphatidylinositol 3-kinase path-
way as a proximal signaling step (9, 10, 48).
Because mice with a targeted deletion of the GLP-1 receptor
have only slightly decreased islet size (47), signaling by GLP-1
does not appear to be essential for -cell and islet develop-
ment. Although it is possible that there is sufﬁcient plasticity in
islet development for some compensation for loss of GLP-1
signaling, it may be that the role of GLP-1 to regulate islet cell
mass is primarily in response to external challenges. Thus
GLP-1 could function as part of a homeostatic system to match
insulin production with chronic nutrient demands. Indeed,
support for this view can be drawn from recent studies impli-
cating GLP-1 signaling in the compensatory -cell hypertro-
phy that develops with insulin resistance (89). However, the
most compelling question raised by the recent ﬁndings of
GLP-1 effects on -cell mass is whether this action can be used
clinically for the treatment of diabetes. If the GLP-1 effects to
increase -cell mass are present in diabetic humans, as they are
in diabetic rodents, it would raise the possibility of a novel
pharmacology that could alter the progressive course of type 2
diabetes.
EFFECTS OF GLP-1 TO LOWER BLOOD GLUCOSE IN
DIABETIC SUBJECTS
Impaired GLP-1 signaling is not likely to contribute sub-
stantially to the metabolic abnormalities of diabetes. However,
recent studies suggest that the secretion of GLP-1 during meal
absorption is slightly but signiﬁcantly lower in people with
type 2 diabetes (85, 94). In addition, the sensitivity of the
-cell to GLP-1 is attenuated in diabetic individuals compared
with nondiabetic persons (41). However, GLP-1 improves
hyperglycemia in diabetic patients, sometimes dramatically.
Continuous intravenous administration of GLP-1 to hypergly-
cemic patients with moderate to poorly controlled type 2
diabetes decreases fasting hyperglycemia to near-normal levels
within 3–4 h (58, 86). This effect of intravenous GLP-1 to
normalize fasting glucose is robust, occurs in almost all pa-
tients (86), and has been attributed to increased insulin release
and decreased glucagon levels (58). Interestingly, fasting hy-
perglycemia was also signiﬁcantly improved in a group of type
1 diabetic subjects with minimal insulin-secretory reserve who
were given intravenous GLP-1, most likely due to suppressed
glucagon secretion (12). Thus, despite having a primary role in
postprandial physiology, exogenous GLP-1 has potent glucose-
lowering effects in fasted diabetic patients.
That GLP-1 is a potent insulin secretagogue in patients with
type 2 diabetes distinguishes it from other insulinotropic gut
peptides such as GIP, CCK, and secretin, which are not
effective in persons with diabetes. In diabetic patients, intra-
venous GLP-1 improves the responsiveness of the -cell to
glucose (56), causes a partial restitution of the ﬁrst phase of
insulin secretion (68, 69), and increases the maximal secretory
capacity (1). Thus GLP-1 treatment corrects several of the
fundamental defects in diabetic -cell function. And because
the insulinotropic effect of GLP-1 is glucose dependent, hypo-
glycemia has rarely been reported in studies with diabetic
patients.
GLP-1 has been administered to diabetic patients by subcu-
taneous injection before meals, and this route of administration
caused a signiﬁcant decrease in the postprandial blood glucose
excursions (20, 83). Despite doses of GLP-1 in these studies
that were in the pharmacological range, the insulin response
was not greatly enhanced, and the most signiﬁcant GLP-1
effect was inhibition of gastric emptying. These studies dem-
onstrate the potential beneﬁt of the gastric effects of GLP-1 in
the treatment of diabetes, although symptoms of nausea have
been reported in some patients. Continuous subcutaneous in-
fusion of GLP-1 via a portable pump to subjects with type 2
diabetes caused signiﬁcant improvements in their glycemic
levels for 1 wk and was well tolerated (44). More recently,
diabetic subjects were given GLP-1 by continuous subcutane-
ous infusion for a period of 6 wk (103). In this study, fasting
and postprandial glucose levels were consistently lower, and
Table 1. Effects of GLP-1 on glucose metabolism
independent of islet hormones: summary of human studies
Mechanism of GLP-1 Action
Studies Reporting
Effect (Ref no.)
Studies Not Finding
Effect (Ref no.)
Insulin action 24, 51 1, 14, 63, 73, 87, 88
Glucose effectiveness 14, 52 87
Glucose uptake 33, 90 81
Glucose production 67, 80 52, 87, 88
GLP-1, glucagon-like peptide 1.
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compared with saline-treated controls. This study demonstrates
that chronic GLP-1 administration is effective and persistent,
and it serves as a proof of principle for the application of the
GLP-1-signaling system to diabetes.
PHARMACOLOGICAL APPLICATION OF GLP-1 TO THE
TREATMENT OF DIABETES
The major limitation of using GLP-1 to treat diabetic pa-
tients is the short half-life of the native compound. The two
NH2-terminal amino acids are cleaved from GLP-1 by the
ubiquitous enzyme dipeptidyl peptidase IV (DPP-IV), and the
circulating half-life of intact GLP-1 is only 1–2 min (19, 40).
Overcoming this hurdle with agents that can give more long-
lived stimulus to the GLP-1 receptor has been a major chal-
lenge in drug development. There are now several compounds
in various stages of preclinical or clinical development for the
treatment of type 2 diabetes that utilize the GLP-1-signaling
pathway. These include GLP-1 receptor agonists with extended
biological half-lives, and inhibitors of DPP-IV that act to
increase circulating levels of endogenous, intact, and bioactive
GLP-1.
GLP-1 Analogs
Several peptide analogs of GLP-1 that are resistant to deg-
radation by DPP-IV have been identiﬁed and have advanced to
clinical trial. The reptilian peptide exendin-4 has 53% se-
quence homology to GLP-1, is a full agonist at the GLP-1
receptor (82), and is resistant to the actions of DPP-IV, result-
ing in a greatly extended duration of action compared with
GLP-1 (22). The antidiabetic actions of exendin-4 have been
conﬁrmed in a variety of rodent strains with diabetes syn-
dromes, as well as in spontaneously diabetic rhesus monkeys
(102). Furthermore, administration of exendin-4 has been
shown to increase pancreatic insulin content and -cell mass in
diabetic rats and mice (96, 101).
In subjects with type 2 diabetes, single subcutaneous injec-
tions of exendin-4 have similar effects to overnight adminis-
tration of intravenous GLP-1 (43). Thus fasting hyperglycemia
decreased from values of near 12 mM to 7m Mo v e r3ha n d
was maintained in this range for 8 h. The improvement in
fasting glycemia was associated with an increase in plasma
insulin and decrease in plasma glucagon, suggesting that
GLP-1-like effects on islet hormone secretion played a major
role. In addition, exendin-4 given to diabetic individuals before
a mixed-nutrient liquid meal signiﬁcantly lowered the post-
prandial glucose excursion (43). Similar to GLP-1, the effects
of exendin-4 on meal-induced glycemia appeared to be the
result of decreased gastric emptying and inhibition of gluca-
gon, in addition to potentiation of insulin secretion. In fact, the
insulin response was actually smaller after exendin-4 than after
placebo, in all likelihood because of the much lower blood
glucose. In that study (43), exendin-4 appeared to be equally
effective in lowering blood glucose in subjects with poorly
controlled diabetes as it was in subjects with good glycemic
control.
Two longer studies of exendin-4 treatment of diabetic pa-
tients have been published (23, 29). In the ﬁrst, exendin-4 was
given once or twice daily for 4 wk. Treated patients had
signiﬁcant reductions in Hb A1c, from 9.1 to 8.3%, noteworthy
in a study of only 1 mo (23). More recently, patients with type
2 diabetes treated with the combination of sulfonylurea and
metformin, but with poor glycemic control (average Hb A1c
9%), were given synthetic exendin-4 for 4 wk (29). Treated
subjects had signiﬁcantly reduced postprandial glucose com-
pared with placebo-treated individuals and a reduction in Hb
A1c of nearly 1% over the month of treatment. Importantly,
serious hypoglycemia was uncommon in both of these trials,
with most events noted in patients taking concurrent sulfonyl-
urea. However, nausea occurred in 15–30% of subjects, al-
though in general this symptom too was relatively mild.
A long-acting derivative of GLP-1, NN2211, is another
agent in advanced clinical development (11, 38). This com-
pound is composed of GLP-1 covalently linked to a hexade-
conyl residue. With the addition of this fatty acid, the GLP-1
complex binds to serum albumin, increasing the duration of
action of NN2211 relative to native GLP-1. Albumin-bound
GLP-1 is less susceptible to degradation by DPP-IV, and it has
reduced renal elimination. The half-life of NN2211 in healthy
volunteers is 12 h (27), so that a single daily injection can
deliver biologically active amounts of GLP-1 for an entire 24-h
period.
Similar to exendin-4 and GLP-1, chronic administration of
NN2211 to diabetic mice decreased glucose levels and in-
creased -cell proliferation and -cell mass (72). In addition,
acute or chronic administration of NN2211 reduced glucose
and increased insulin levels, suppressed glucagon release, and
delayed gastric emptying in glucose-intolerant minipigs, result-
ing in a marked reduction of serum fructosamine levels (71).
In patients with type 2 diabetes, a single subcutaneous
injection of NN2211 reduced glucose levels to near-normal
levels overnight and lowered postprandial glucose excursions,
at least partly, by enhancing increased meal-stimulated insulin
secretion (38). Suppression of meal-stimulated glucagon levels
and delay of gastric emptying were also conﬁrmed in patients
with type 2 diabetes, and the plasma half-life of NN2211 was
similar (10 h) to that reported previously in healthy volunteers.
However, as with exendin-4 or native GLP-1, nausea and
vomiting are the most common side effects and are generally a
function of the dose administered. For example, in healthy
volunteers given NN2211 to assess tolerability of the drug, the
incidence of nausea and vomiting occurred in all of the subjects
receiving the highest dose (20 g/kg) and decreased at lower
doses (27). In a study of diabetic patients, nausea was reported
in 2 of 11 patients after injection of 10 g/kg (38).
In sum, the GLP-1 receptor agonists exendin-4 and NN2211
are promising agents that have been shown to share the
multiple positive metabolic effects of GLP-1 (stimulation of
insulin release in a glucose-dependent manner, suppression of
glucagon release, and delay of gastric emptying) in patients
with type 2 diabetes. Their extended duration of action permits
once or twice a day administration and similar effectiveness to
continuously infused GLP-1. Although these agents are well
tolerated over short trials, it remains to be seen whether the
relatively frequent GI side effects will limit their utility.
DPP-IV Inhibitors
Given the rapid inactivation of GLP-1 by DPP-IV, methods
to inactivate this protease are a second major strategy to
increase plasma GLP-1 levels, and several have been devel-
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tory peptides, including GIP (53), the effects of these agents
cannot be entirely attributed to GLP-1. However, most of the
other known peptides acted on by DPP-IV do not have known
roles in glucose homeostasis, and GIP has been consistently
shown to be inactive in diabetic patients. Because plasma
levels of intact GLP-1 increase after inhibition of DPP-IV,
much of the clinical effect of DPP-IV inhibitors has been
ascribed to GLP-1.
Several orally effective inhibitors of DPP-IV have been
identiﬁed that exert antidiabetic actions in various hyperglyce-
mic animal models. For example, acute administration of
DPP-IV inhibitors to Zucker fatty rats increased the percentage
of intact GLP-1 from 20 to 100%, stimulated insulin release,
and improved glucose tolerance (3). When Zucker fatty rats
were treated with a DPP-IV inhibitor for 3 mo, there was
improved glucose tolerance as well as enhanced insulin secre-
tion and insulin action (66). DPP-IV inhibition was also effec-
tive in obese, glucose-intolerant monkeys (93). Similar to
GLP-1 and GLP-1 analogs, DPP-IV inhibitors do not appear to
exhibit tachyphylaxis. For example, there was no waning of
effectiveness to improve glucose tolerance over 8-wk treatment
of glucose-intolerant mice (70).
Several DPP-IV inhibitors are in clinical trials. Recently the
results from a trial of NVP-DPP728 have been reported (2). In
this study, NVP-DPP728 (100 mg 3 times a day or 150 mg
twice a day) or placebo was administered for 4 wk in patients
with type 2 diabetes and relatively mild hyperglycemia (fasting
plasma glucose 8.6 mmol/l, Hb A1c 7.4%) who were not
treated with medications. Treatment with the DPP-IV inhibitor
signiﬁcantly reduced glucose levels throughout the day, and
insulin levels were also slightly reduced. However, in the
context of lower glucose, it is likely that the -cell responsive-
ness to glucose was actually increased, a ﬁnding often reported
for GLP-1. Fasting plasma glucose was modestly but signiﬁ-
cantly reduced in patients receiving NVP-DPP728, and Hb A1c
decreased by 0.5% after 4 wk. Treatment with NVP-DPP728
was well tolerated: one of 61 patients had an episode of
conﬁrmed hypoglycemia, and two patients reported mild nau-
sea during active treatment.
Because DPP-IV metabolizes a number of regulatory pep-
tides, there has been some concern about using agents that
inhibit this enzyme for prolonged periods. However, except for
GLP-1, there seem to be alternative enzymatic pathways for
the degradation of most DPP-IV substrates. Rats with a spon-
taneous null mutation of the DPP-IV gene and mice with
targeted deletions of DPP-IV are normal except for a tendency
toward enhanced glucose tolerance (50, 64).
It seems likely that both GLP-1 analogs and DPP-IV inhib-
itors will have a place in the treatment of diabetes. The analogs
have speciﬁc actions that can be attributed to GLP-1 receptor
signaling and can be administered in pharmacological doses.
However, current versions of these agents must be injected,
and side effects, particularly nausea, are potentially limiting.
DPP-IV inhibitors are orally available and have been well
tolerated, with only minimal adverse effects noted in the
clinical experience to date. However, the potency of these
agents is limited by the production of endogenous GLP-1 (and
potentially other peptides). How these strengths and weak-
nesses of GLP-1-related treatments shape their clinical appli-
cation will be an interesting outcome of further clinical trials
and postmarketing follow-up.
SUMMARY
GLP-1 is an incretin that is essential for normal glucose
tolerance. It is the ﬁrst insulinotropic GI hormone to be
identiﬁed that is effective in diabetic as well as nondiabetic
persons. The effect of GLP-1 to lower blood glucose is likely
due to effects on several processes, including gastric motility,
food intake, and possibly glucose production and/or glucose
uptake, as well as islet hormone secretion. Although the mech-
anisms by which GLP-1 controls these processes in vivo are
still being clariﬁed, it appears that some, like gastric emptying
and satiety, could be mediated through a visceral neural path-
way. One tenable hypothesis is that this neural circuit, initiated
from sites innervated by vagal afferents, integrates the spec-
trum of GLP-1 effects. Pharmacological administration of
GLP-1 or GLP-1 receptor agonists, or elevation of circulating
GLP-1 with DPP-IV inhibitors, offers promise that the GLP-1
system can be effectively used for the treatment of diabetes.
Given the range of responses that are mediated through the
GLP-1 receptor, these new agents will add new and comple-
mentary options for diabetic patients.
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